We’re pleased to announce FDA Fast Track Designation for
Sanatate
We’re pleased to announce FDA Fast Track Designation for ABBV-CLS-628, an investigational therapy developed in collaboration with AbbVie for Autosomal Dominant Polycystic Kidney Disease (ADPKD). ABBV-CLS-628 is now in a Phase 2 clinical trial. Read more: https://t.co/c8JB1HyvsQ https://t.co/dTSPX6S9dg
din zilele anterioare